- Home
- IMCR vs CRTO Comparison
IMCR vs CRTO Comparison
Compare IMCR & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- CRTO
- Stock Information
- Founded
- IMCR 2008
- CRTO 2005
- Country
- IMCR United Kingdom
- CRTO France
- Employees
- IMCR N/A
- CRTO N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- CRTO Advertising
- Sector
- IMCR Health Care
- CRTO Consumer Discretionary
- Exchange
- IMCR Nasdaq
- CRTO Nasdaq
- Market Cap
- IMCR 1.8B
- CRTO 1.2B
- IPO Year
- IMCR 2021
- CRTO 2013
- Fundamental
- Price
- IMCR $35.24
- CRTO $22.01
- Analyst Decision
- IMCR Buy
- CRTO Buy
- Analyst Count
- IMCR 8
- CRTO 9
- Target Price
- IMCR $57.00
- CRTO $39.11
- AVG Volume (30 Days)
- IMCR 281.5K
- CRTO 291.9K
- Earning Date
- IMCR 11-05-2025
- CRTO 10-29-2025
- Dividend Yield
- IMCR N/A
- CRTO N/A
- EPS Growth
- IMCR N/A
- CRTO 44.35
- EPS
- IMCR N/A
- CRTO 2.38
- Revenue
- IMCR $356,145,000.00
- CRTO $1,946,032,000.00
- Revenue This Year
- IMCR $31.83
- CRTO N/A
- Revenue Next Year
- IMCR $8.50
- CRTO $2.19
- P/E Ratio
- IMCR N/A
- CRTO $9.24
- Revenue Growth
- IMCR 26.78
- CRTO N/A
- 52 Week Low
- IMCR $23.15
- CRTO $21.44
- 52 Week High
- IMCR $39.33
- CRTO $47.27
- Technical
- Relative Strength Index (RSI)
- IMCR 56.75
- CRTO 36.33
- Support Level
- IMCR $35.33
- CRTO $21.44
- Resistance Level
- IMCR $37.16
- CRTO $23.80
- Average True Range (ATR)
- IMCR 1.36
- CRTO 0.79
- MACD
- IMCR 0.32
- CRTO -0.22
- Stochastic Oscillator
- IMCR 53.39
- CRTO 15.00
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.